A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma

Plasma Cell Myeloma Clinical Trial

Official title:

An Open-label, Dose-escalation and Multi-center Study to Evaluate the Safety, Pharmacokinetics and Efficacy of SAR650984 (Isatuximab) in Patients With Relapsed/Refractory Multiple Myeloma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02514668
• Other study ID #: TED14154
• Secondary ID: U1111-1163-1073
• Status: Completed
• Phase: Phase 1
• Start date: September 1, 2015
• Est. completion date: December 2, 2021

Study information

• Verified date: April 2022
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Primary Objective: - Part A: To evaluate the safety of SAR650984 (isatuximab) in patients with relapsed/refractory multiple myeloma (RRMM). - Part B: To evaluate the activity of SAR650984 (isatuximab) as assessed by overall response rate (ORR) in RRMM patients previously treated with daratumumab. Secondary Objectives: - Part A: - To determine the pharmacokinetics (PK) of SAR650984 (isatuximab) in patients with RRMM. - Part B: - To evaluate the safety of SAR650984 (isatuximab). - To evaluate the efficacy of SAR650984 (isatuximab) as assessed by duration of response (DOR), clinical benefit rate (CBR) and progression free survival (PFS). - To assess the pharmacokinetics (PK) of SAR650984 (isatuximab) and daratumumab at baseline. - To evaluate the immunogenicity of SAR650984 (isatuximab).

Description:

Study duration for an individual patient will include a screening period for inclusion of up to 3 weeks, the treatment period and, a follow up period. Treatment with SAR650984 (isatuximab) may continue until disease progression, unacceptable adverse event, or other reason for discontinuation. After study treatment discontinuation, an end of treatment visit will be done at 30 days to assess safety and PK, and at 30 and 60 days for anti-drug antibody (ADA). If the ADA is positive at Day 60, ADA will be repeated every 30 days until ADA is negative. Patients with partial remission or better who discontinue treatment for reasons other than progression of disease will be followed monthly until progression or initiation of subsequent therapy, the final analysis cutoff date, whichever comes first.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 55
• Est. completion date: December 2, 2021
• Est. primary completion date: December 2, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

Part A

• Patients must have a known diagnosis of multiple myeloma (MM) with evidence of measurable disease, as defined below, and have evidence of disease progression based

on International Myeloma Working Group (IMWG) criteria:

• Serum M-protein =1g/dL, or urine M-protein =200 mg/24 hours, OR
• In the absence of measurable M-protein, serum immunoglobulin free light chain =10 mg/dL, and abnormal serum immunoglobulin kappa lambda free light chain ratio.
• Patients must have received at least 3 prior lines of therapy for MM and must include treatment with an immunomodulatory drug (IMiD) (for =2 cycles or =2 months of treatment) and a proteasome inhibitor (for =2 cycles or =2 months of treatment). Induction therapy and stem cell transplant (± maintenance) will be considered as one regimen within a line, OR
• Patients whose disease is double refractory to an IMiD and a proteasome inhibitor. For patients who have received more than one type of IMiD and proteasome inhibitor, their disease must be refractory to the most recent one.
• Patients must have achieved a minimal response (MR) or better to at least one prior line of therapy.
• Patients must have received an alkylating agent (for =2 cycles or =2 months of treatment) either alone or in combination with other MM treatments (history of stem cell transplant is acceptable). Treatment with high-dose Melphalan for stem cell transplantation meets this requirement.
• Signed written informed consent and be willing and able to complete all study-related procedures. Part B
• Patients must have a known diagnosis of multiple myeloma (MM) with evidence of measurable disease, as defined below, and have evidence of disease progression based

on International Myeloma Working Group (IMWG) criteria:

• Serum M-protein =1g/dL, or urine M-protein =200 mg/24 hours, OR
• In the absence of measurable M-protein, serum immunoglobulin free light chain =10 mg/dL, and abnormal serum immunoglobulin kappa lambda free light chain ratio.
• Patients must have received at least 3 cycles of daratumumab treatment with at least 6 weeks from the last treatment with daratumumab to the first study treatment OR at least 2 cycles of daratumumab treatment in case another therapy is given between daratumumab and isatuximab with at least 12 weeks from the last treatment with daratumumab to the first study treatment.
• Patients must have achieved MR or better to at least 1 prior line of therapy.
• Signed written informed consent and be willing and able to complete all study-related procedures.

Exclusion criteria:

• Patients <18 years old.
• Eastern Cooperative Oncology Group (ECOG) performance status >2.
• Poor bone marrow reserve.
• Poor organ function.
• Known intolerance/hypersensitivity to IMiDs, dexamethasone, boron or mannitol, sucrose, histidine, or polysorbate 80.
• Any serious active disease (including clinically significant infection that is chronic, recurrent, or active) or comorbid condition, which, in the opinion of the Investigator, could interfere with the safety, the compliance with the study, or with the interpretation of the results.
• Any severe underlying medical conditions including presence of laboratory abnormalities, which could impair the ability to participate in the study or the interpretation of its results. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell
• Plasma Cell Myeloma

Intervention

Drug:
• Isatuximab
Pharmaceutical form: solution for infusion Route of administration: intravenous

Locations

Country	Name	City	State
Czechia	Investigational Site Number 203002	Brno
Czechia	Investigational Site Number 203001	Praha 2
France	Investigational Site Number 250008	Creteil Cedex
France	Investigational Site Number 250005	Montpellier Cedex 5
France	Investigational Site Number 250002	Nantes Cedex 01
France	Investigational Site Number 250004	Pessac
France	Investigational Site Number 250001	Poitiers
France	Investigational Site Number 250006	Vandoeuvre-Les-Nancy Cedex
United States	Investigational Site Number 840013	Canton	Ohio
United States	Investigational Site Number 840011	Detroit	Michigan
United States	Investigational Site Number 840010	Durham	North Carolina
United States	Investigational Site Number 840005	Hackensack	New Jersey
United States	Investigational Site Number 840006	Milwaukee	Wisconsin
United States	Investigational Site Number 840001	Nashville	Tennessee
United States	Investigational Site Number 840015	Saint Louis	Missouri
United States	Investigational Site Number 840002	Salt Lake City	Utah
United States	Investigational Site Number 840004	San Francisco	California
United States	Investigational Site Number 840003	Scottsdale	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Sanofi

Countries where clinical trial is conducted

United States,  Czechia,  France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Part A: Dose Limiting Toxicities (DLTs)		Up to 4 weeks
Primary	Part A: Number of patients with adverse events (AEs) and changes in laboratory tests and vital signs according to the National Cancer Institute - Common Toxicity Criteria (NCI-CTC) version 4.03 grade scaling		Up to 30 days following the last administration of study treatment or up to 12 months for ongoing related AE, ongoing serious AE and new related AE
Primary	Part B: Overall Response Rate (ORR)		4 months
Secondary	Assessment of PK parameters: partial area under the serum concentration time curve (AUC)		1 week after first treatment
Secondary	Assessment of PK parameters: maximum observed concentration (Cmax)		1 week after first treatment
Secondary	Part B: Number of patients with AEs and changes in laboratory tests and vital signs according to the National Cancer Institute - Common Toxicity Criteria (NCI-CTC) version 4.03 grade scaling		Up to 30 days following the last administration of study treatment or up to 12 months for ongoing related AE, ongoing serious AE and new related AE
Secondary	Part B: Duration of Response (DOR)		Up to 12 months from the last patient in
Secondary	Part B: Clinical Benefit Rate (CBR)		Up to 12 months from the last patient in
Secondary	Part B: Progression Free Survival (PFS)		Up to 12 months from the last patient in
Secondary	Part B: Levels of isatuximab antibodies		Up to 12 months from the last patient in